Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
solifenacin succinate
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HGP1103 is a development code for a generic formulation of **solifenacin succinate**, a competitive muscarinic acetylcholine receptor antagonist. Developed by **Hanmi Pharmaceutical**, it is primarily indicated for the treatment of **overactive bladder (OAB)**, characterized by symptoms such as urinary urgency, frequency, and urge incontinence. Solifenacin exhibits selectivity for the **M3 receptor** subtype, which mediates bladder smooth muscle contraction. By blocking these receptors, HGP1103 reduces detrusor muscle overactivity. In clinical development, HGP1103 has served as a reference agent in pharmacokinetic studies and as a component in the development of fixed-dose combinations, such as HIP1503 (solifenacin/tamsulosin).
- Brand names
- Vesigum
- Other names
- solifenacin
02
Targets
CHRM3 (M3)
Beyond the preview
Go deeper on solifenacin succinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on solifenacin succinate.